HRP20110012T1 - Farmaceutski pripravak - Google Patents

Farmaceutski pripravak Download PDF

Info

Publication number
HRP20110012T1
HRP20110012T1 HR20110012T HRP20110012T HRP20110012T1 HR P20110012 T1 HRP20110012 T1 HR P20110012T1 HR 20110012 T HR20110012 T HR 20110012T HR P20110012 T HRP20110012 T HR P20110012T HR P20110012 T1 HRP20110012 T1 HR P20110012T1
Authority
HR
Croatia
Prior art keywords
tablet
layer according
serum concentrations
spray
sorbitol
Prior art date
Application number
HR20110012T
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Ruediger
Maerz Frieder
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38179677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20110012T1 publication Critical patent/HRP20110012T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20110012T 2007-03-14 2011-01-10 Farmaceutski pripravak HRP20110012T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104157A EP1970053A1 (en) 2007-03-14 2007-03-14 Pharmaceutical composition
PCT/EP2008/053009 WO2008110599A1 (en) 2007-03-14 2008-03-13 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20110012T1 true HRP20110012T1 (hr) 2011-02-28

Family

ID=38179677

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110012T HRP20110012T1 (hr) 2007-03-14 2011-01-10 Farmaceutski pripravak

Country Status (36)

Country Link
US (1) US20100143465A1 (pl)
EP (2) EP1970053A1 (pl)
JP (1) JP5742045B2 (pl)
KR (1) KR101503674B1 (pl)
CN (1) CN101641084B (pl)
AR (1) AR065726A1 (pl)
AT (1) ATE493119T1 (pl)
AU (1) AU2008225754B2 (pl)
BR (1) BRPI0808797A2 (pl)
CA (1) CA2680608C (pl)
CL (1) CL2008000733A1 (pl)
CO (1) CO6220927A2 (pl)
CY (1) CY1111350T1 (pl)
DE (1) DE602008004217D1 (pl)
DK (1) DK2120884T3 (pl)
EA (1) EA018574B1 (pl)
EC (1) ECSP099629A (pl)
ES (1) ES2358770T3 (pl)
HK (1) HK1140692A1 (pl)
HR (1) HRP20110012T1 (pl)
IL (1) IL200125A (pl)
MA (1) MA31251B1 (pl)
MX (1) MX2009009201A (pl)
MY (1) MY145089A (pl)
NZ (1) NZ580185A (pl)
PE (1) PE20090165A1 (pl)
PL (1) PL2120884T3 (pl)
PT (1) PT2120884E (pl)
RS (1) RS51584B (pl)
SI (1) SI2120884T1 (pl)
TN (1) TN2009000371A1 (pl)
TW (1) TWI406678B (pl)
UA (1) UA96982C2 (pl)
UY (1) UY30961A1 (pl)
WO (1) WO2008110599A1 (pl)
ZA (1) ZA200905224B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
US20100247649A1 (en) * 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2291177A2 (en) 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ301070B6 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
GB0822171D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Temisartan formulations
DK2432452T3 (en) * 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
WO2013142314A1 (en) * 2012-03-19 2013-09-26 Althera Life Sciences, Llc Oral tablet formulation consisting of immediate release rosuv astatin and extended release metformin
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
JP6096328B2 (ja) * 2014-02-10 2017-03-15 富士フイルム株式会社 口腔内崩壊錠
BE1021954B1 (nl) * 2014-06-05 2016-01-28 Syral Belgium Nv Samenstelling van sorbitol met lage friabiliteit
FR3023128B1 (fr) 2014-07-01 2017-11-10 Roquette Freres Nouvelle composition edulcorante
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN109316451B (zh) * 2017-07-31 2022-07-01 武汉朗来科技发展有限公司 治疗高血压和相关疾病的口服固体制剂
MX2020011541A (es) 2018-05-02 2020-11-24 Ferring Bv Formulaciones farmaceuticas mejoradas.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245170A1 (de) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
EP2260833B1 (en) * 2002-01-16 2012-11-21 Boehringer Ingelheim Pharma GmbH & Co. KG Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
UA89065C2 (ru) * 2004-11-05 2009-12-25 Бёрингэр Ингэльхайм Интэрнациональ Гмбх Двухслойная таблетка, которая содержит телмисартан и амлодипин
CN101080225A (zh) * 2004-12-17 2007-11-28 贝林格尔·英格海姆国际有限公司 包含替米沙坦及氢氯噻嗪的组合治疗
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy

Also Published As

Publication number Publication date
DE602008004217D1 (de) 2011-02-10
AU2008225754A1 (en) 2008-09-18
CN101641084A (zh) 2010-02-03
SI2120884T1 (sl) 2011-04-29
CY1111350T1 (el) 2015-08-05
EA018574B1 (ru) 2013-09-30
KR101503674B1 (ko) 2015-03-18
DK2120884T3 (da) 2011-02-07
HK1140692A1 (en) 2010-10-22
EA200901169A1 (ru) 2010-04-30
ES2358770T3 (es) 2011-05-13
PE20090165A1 (es) 2009-03-31
CA2680608A1 (en) 2008-09-18
PT2120884E (pt) 2011-02-10
PL2120884T3 (pl) 2011-05-31
KR20090119998A (ko) 2009-11-23
MY145089A (en) 2011-12-30
IL200125A (en) 2012-01-31
ECSP099629A (es) 2009-10-30
TW200900095A (en) 2009-01-01
CO6220927A2 (es) 2010-11-19
NZ580185A (en) 2011-11-25
EP1970053A1 (en) 2008-09-17
JP5742045B2 (ja) 2015-07-01
ZA200905224B (en) 2010-04-28
EP2120884B1 (en) 2010-12-29
UY30961A1 (es) 2008-10-31
BRPI0808797A2 (pt) 2013-01-15
MA31251B1 (fr) 2010-03-01
MX2009009201A (es) 2009-09-08
CL2008000733A1 (es) 2008-07-04
ATE493119T1 (de) 2011-01-15
US20100143465A1 (en) 2010-06-10
AR065726A1 (es) 2009-06-24
CN101641084B (zh) 2013-04-10
WO2008110599A1 (en) 2008-09-18
IL200125A0 (en) 2010-04-15
UA96982C2 (ru) 2011-12-26
EP2120884A1 (en) 2009-11-25
AU2008225754B2 (en) 2013-04-04
TWI406678B (zh) 2013-09-01
JP2010530844A (ja) 2010-09-16
CA2680608C (en) 2015-06-16
RS51584B (en) 2011-08-31
TN2009000371A1 (fr) 2010-12-31

Similar Documents

Publication Publication Date Title
HRP20110012T1 (hr) Farmaceutski pripravak
US10960052B2 (en) Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
HRP20150459T1 (hr) Farmaceutski pripravci na bazi superstruktura antagonista/blokatora angiontenzinskih receptora (arb) i inhibitora neutralne endopeptidaze (nep)
DE602007013380D1 (de) Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
DE502005009109D1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
PE20080519A1 (es) Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas
AR071375A1 (es) Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2009008006A3 (en) Pharmaceutical compositions for gastrointestinal drug delivery
AU2014374552A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
WO2016120378A1 (en) Tablets comprising glp-1 agonist and enteric coating
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
DK2155229T3 (da) Sammensætning til transmukosal indgivelse af polypeptider
JP2010540547A5 (pl)
Zhang et al. Using dissolution and pharmacokinetics studies of crystal form to optimize the original iloperidone
JP2015522652A5 (pl)
Scalise et al. Studying interactions of drugs with cell membrane nutrient transporters: new frontiers of proteoliposome nanotechnology
Hussain et al. Liquisolid Technique: a Novel Tool to Develop Aceclofenac-Loaded Eudragit L-100 and RS-100-Based Sustained Release Tablets
JP2007509965A5 (pl)
Hashem et al. Formulation and in vitro and in vivo evaluation of lipid-based terbutaline sulphate bi-layer tablets for once-daily administration
Joharapurkar et al. In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport
MX2012001393A (es) Composiciones farmacéuticas de liberación controlada de milnacipran.
CL2007002807A1 (es) Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
WO2008037224A3 (es) Forma de dosificación de liberación controlada que contiene lercanidipina y un ácido que mejora el funcionamiento
Jain et al. RP-HPLC Assay Method for simultaneous determination of Perindopril Erbumine and Indapamide combination in bulk and tablet dosage form